25 results on '"Bayley, Rachel"'
Search Results
2. Altered leukocyte signalling thresholds in rheumatoid arthritis through changes in the function of the protein tyrosine phosphatase PTPN22/LYP
- Author
-
Bayley, Rachel
- Subjects
616.7 ,R Medicine (General) - Abstract
Rheumatoid arthritis (RA) results from complex interactions between genetic and environmental risk factors. Two examples of these are the genetic variant PTPN22 R620W, a disease-associated form of the protein tyrosine phosphatase (PTP) Lyp and cigarette smoking (CS). Epidemiological studies have identified interactions between R620W and CS, but the biological mechanisms behind these interactions are unclear. Lyp is expressed by all leukocytes and changes in leukocyte function are implicated in the pathogenesis of RA. Thus the aim of this study was to characterise the effects of R620W and CS on leukocyte signalling, to determine possible mechanisms by which these factors could interact to promote the development of RA. An assay to measure the specific activity of the Lyp phosphatase was developed. Healthy controls and RA patients were recruited and genotyped for the PTPN22 R620W variant. Following determination of genotype, neutrophils and CD4+ T cells were isolated and cell function assessed following cigarette smoke extract (CSE) treatment. R620W in T lymphocytes increased Lyp phosphatase activity, decreased Lyp substrate phosphorylation and increased production of the pro-inflammatory cytokines IFN-γ and TNF-α. CSE treatment decreased T cell receptor signalling which was characterised by decreased PTP activity, decreased calcium (Ca2+) flux and decreased cytokine production. R620W in neutrophils was associated with increased neutrophil activation and functions including Ca2+ flux, reactive oxygen species production and migration. Overall these data suggest that R620W may facilitate RA development and persistence by promoting the generation of inflammatory T cells and by enhancing neutrophil activation and migration. CS may promote further signalling dysfunction by oxidising the proteins controlling leukocyte signalling. These separate pathways leading to altered Lyp function may act additively or synergistically to promote the immune disturbances which underpin the development of RA.
- Published
- 2014
3. A heterozygousCEBPAmutation disrupting the bZIP domain causes MDS disease progression
- Author
-
Almaghrabi, Ruba, primary, Alyayhawi, Yara, additional, Keane, Peter, additional, Ward, Carl, additional, Bayley, Rachel, additional, Sargas, Claudia, additional, Menendez, Pablo, additional, Murphy, George J., additional, Sobahy, Turki, additional, Baghdadi, Mohammed A., additional, Flemban, Arwa F, additional, Kabrah, Saeed, additional, Akerman, Ildem, additional, Raghavan, Manoj, additional, Barragan, Eva, additional, Bonifer, Constanze, additional, and Garcia, Paloma, additional
- Published
- 2023
- Full Text
- View/download PDF
4. Differential Expression of CD148 on leucocyte subsets in inflammatory arthritis
- Author
-
Dave, Richa K, Naylor, Amy J, Young, Stephen P, Bayley, Rachel, Hardie, Debbie L, Haworth, Oliver, Rider, David A, Cook, Andrew D, Buckley, Christopher D, and Kellie, Stuart
- Abstract
Abstract Introduction Monocytic cells play a central role in the aetiology of rheumatoid arthritis, and manipulation of the activation of these cells is an approach currently under investigation to discover new therapies for this and associated diseases. CD148 is a transmembrane tyrosine phosphatase that is highly expressed in monocytes and macrophages and, since this family of molecules plays an important role in the regulation of cell activity, CD148 is a potential target for the manipulation of macrophage activation. For any molecule to be considered a therapeutic target, it is important for it to be increased in activity or expression during disease. Methods We have investigated the expression of CD148 in two murine models of arthritis and in joints from rheumatoid arthritis (RA) patients using real-time PCR, immunohistochemistry, and studied the effects of proinflammatory stimuli on CD148 activity using biochemical assays. Results We report that CD148 mRNA is upregulated in diseased joints of mice with collagen-induced arthritis. Furthermore, we report that in mice CD148 protein is highly expressed in infiltrating monocytes of diseased joints, with a small fraction of T cells also expressing CD148. In human arthritic joints both T cells and monocytes expressed high levels of CD148, however, we show differential expression of CD148 in T cells and monocytes from normal human peripheral blood compared to peripheral blood from RA and both normal and RA synovial fluid. Finally, we show that synovial fluid from rheumatoid arthritis patients suppresses CD148 phosphatase activity. Conclusions CD148 is upregulated in macrophages and T cells in human RA samples, and its activity is enhanced by treatment with tumour necrosis factor alpha (TNFα), and reduced by synovial fluid or oxidising conditions. A greater understanding of the role of CD148 in chronic inflammation may lead to alternative therapeutic approaches to these diseases.
- Published
- 2013
5. Figure S1 to S7 from MYBL2 Supports DNA Double Strand Break Repair in Hematopoietic Stem Cells
- Author
-
Bayley, Rachel, primary, Blakemore, Daniel, primary, Cancian, Laila, primary, Dumon, Stephanie, primary, Volpe, Giacomo, primary, Ward, Carl, primary, Almaghrabi, Ruba, primary, Gujar, Jidnyasa, primary, Reeve, Natasha, primary, Raghavan, Manoj, primary, Higgs, Martin R., primary, Stewart, Grant S., primary, Petermann, Eva, primary, and García, Paloma, primary
- Published
- 2023
- Full Text
- View/download PDF
6. Table S1 from MYBL2 Supports DNA Double Strand Break Repair in Hematopoietic Stem Cells
- Author
-
Bayley, Rachel, primary, Blakemore, Daniel, primary, Cancian, Laila, primary, Dumon, Stephanie, primary, Volpe, Giacomo, primary, Ward, Carl, primary, Almaghrabi, Ruba, primary, Gujar, Jidnyasa, primary, Reeve, Natasha, primary, Raghavan, Manoj, primary, Higgs, Martin R., primary, Stewart, Grant S., primary, Petermann, Eva, primary, and García, Paloma, primary
- Published
- 2023
- Full Text
- View/download PDF
7. Data from MYBL2 Supports DNA Double Strand Break Repair in Hematopoietic Stem Cells
- Author
-
Bayley, Rachel, primary, Blakemore, Daniel, primary, Cancian, Laila, primary, Dumon, Stephanie, primary, Volpe, Giacomo, primary, Ward, Carl, primary, Almaghrabi, Ruba, primary, Gujar, Jidnyasa, primary, Reeve, Natasha, primary, Raghavan, Manoj, primary, Higgs, Martin R., primary, Stewart, Grant S., primary, Petermann, Eva, primary, and García, Paloma, primary
- Published
- 2023
- Full Text
- View/download PDF
8. New perspectives on epigenetic modifications and PARP inhibitor resistance in HR-deficient cancers
- Author
-
Bayley, Rachel, primary, Sweatman, Ellie, additional, and Higgs, Martin R., additional
- Published
- 2023
- Full Text
- View/download PDF
9. Chapter 11 Metabolomics in the Analysis of Inflammatory Diseases
- Author
-
Clay, Elizabeth, Kapoor, Sabrina, Bayley, Rachel, Wallace, Graham R., Young, Stephen P., Fitzpatrick, Martin, R., Graham, and P., Stephen
- Subjects
molecular biology ,biochemistry ,genetics ,Hypoxia (medical) ,Inflammation ,Lactic acid ,Metabolism ,Metabolite ,Metabolomics ,Rheumatoid arthritis ,bic Book Industry Communication::P Mathematics & science::PS Biology, life sciences::PSB Biochemistry - Abstract
Most infections and traumatic injuries are cleared or repaired relatively rapidly and metabolic homoeostasis is soon restored. However, there is a broad range of inflammatory diseases which involve chronic activation of the immune system and, as a result, chronic persistent inflammation. We have been studying the metabolic consequences of chronic inflammatory diseases with the aim of identifying metabolic fingerprints which may provide clues about why the localised tissue disease persists.
- Published
- 2012
- Full Text
- View/download PDF
10. H3K4 methylation by SETD1A/BOD1L facilitates RIF1-dependent NHEJ
- Author
-
Bayley, Rachel, primary, Borel, Valerie, additional, Moss, Rhiannon J., additional, Sweatman, Ellie, additional, Ruis, Philip, additional, Ormrod, Alice, additional, Goula, Amalia, additional, Mottram, Rachel M.A., additional, Stanage, Tyler, additional, Hewitt, Graeme, additional, Saponaro, Marco, additional, Stewart, Grant S., additional, Boulton, Simon J., additional, and Higgs, Martin R., additional
- Published
- 2022
- Full Text
- View/download PDF
11. The autoimmune-associated genetic variant PTPN22 R620W enhances neutrophil activation and function in patients with rheumatoid arthritis and healthy individuals
- Author
-
Bayley, Rachel, Kite, Kerry A, McGettrick, Helen M, Smith, Jacqueline P, Kitas, George D, Buckley, Christopher D, and Young, Stephen P
- Published
- 2015
- Full Text
- View/download PDF
12. Histone Methylation by SETD1A Protects Nascent DNA through the Nucleosome Chaperone Activity of FANCD2
- Author
-
Higgs, Martin R., Sato, Koichi, Reynolds, John J., Begum, Shabana, Bayley, Rachel, Goula, Amalia, Vernet, Audrey, Paquin, Karissa L., Skalnik, David G., Kobayashi, Wataru, Takata, Minoru, Howlett, Niall G., Kurumizaka, Hitoshi, Kimura, Hiroshi, and Stewart, Grant S.
- Subjects
DNA Replication ,replication stress ,Fanconi Anemia Complementation Group D2 Protein ,FANCD2 ,DNA ,Histone-Lysine N-Methyltransferase ,Methylation ,Article ,Epigenesis, Genetic ,Nucleosomes ,Histones ,A549 Cells ,SETD1A ,Humans ,Rad51 Recombinase ,histone methylation ,lysine methyltransferase ,replication fork replication ,BOD1L ,HeLa Cells ,Molecular Chaperones - Abstract
Summary Components of the Fanconi anemia and homologous recombination pathways play a vital role in protecting newly replicated DNA from uncontrolled nucleolytic degradation, safeguarding genome stability. Here we report that histone methylation by the lysine methyltransferase SETD1A is crucial for protecting stalled replication forks from deleterious resection. Depletion of SETD1A sensitizes cells to replication stress and leads to uncontrolled DNA2-dependent resection of damaged replication forks. The ability of SETD1A to prevent degradation of these structures is mediated by its ability to catalyze methylation on Lys4 of histone H3 (H3K4) at replication forks, which enhances FANCD2-dependent histone chaperone activity. Suppressing H3K4 methylation or expression of a chaperone-defective FANCD2 mutant leads to loss of RAD51 nucleofilament stability and severe nucleolytic degradation of replication forks. Our work identifies epigenetic modification and histone mobility as critical regulatory mechanisms in maintaining genome stability by restraining nucleases from irreparably damaging stalled replication forks., Graphical Abstract, Highlights • Methylation of H3K4 by SETD1A maintains genome stability during replication stress • SETD1A and H3K4 methylation stabilize RAD51 nucleofilaments to protect nascent DNA • SETD1A-dependent H3K4 methylation enhances FANCD2-dependent histone remodeling • Histone mobility stabilizes RAD51 nucleofilaments to inhibit fork degradation, Higgs et al. identify histone H3K4 methylation by SETD1A as essential to prevent genome instability during replication stress by enhancing FANCD2-dependent nucleosome remodeling. Loss of SETD1A or deficiencies in H3 mobilization by FANCD2 leads to RAD51 nucleofilament instability and severe nucleolytic degradation of stalled replication forks.
- Published
- 2018
13. Metabolomics in the Analysis of Inflammatory Diseases
- Author
-
Kapoor, Sabrina, primary, Fitzpatrick, Martin, additional, Clay, Elizabeth, additional, Bayley, Rachel, additional, R., Graham, additional, and P., Stephen, additional
- Published
- 2012
- Full Text
- View/download PDF
14. The productivity limit of manufacturing blood cell therapy in scalable stirred bioreactors
- Author
-
Bayley, Rachel, Ahmed, Forhad, Glen, Katie, McCall, Mark, Stacey, Adrian, and Thomas, Robert
- Subjects
productivity ,Blood Cells ,Erythroblasts ,Cell- and Tissue-Based Therapy ,Cell Count ,Cell Differentiation ,culture ,Oxygen ,bioreactor ,Bioreactors ,blood ,cost ,Metabolome ,red cell ,Cytokines ,Humans ,erythrocyte ,Research Articles ,manufacture ,Research Article ,Cell Proliferation - Abstract
Manufacture of red blood cells (RBCs) from progenitors has been proposed as a method to reduce reliance on donors. Such a process would need to be extremely efficient for economic viability given a relatively low value product and high (2 × 1012) cell dose. Therefore, the aim of these studies was to define the productivity of an industry standard stirred‐tank bioreactor and determine engineering limitations of commercial red blood cells production. Cord blood derived CD34+ cells were cultured under erythroid differentiation conditions in a stirred micro‐bioreactor (Ambr™). Enucleated cells of 80% purity could be created under optimal physical conditions: pH 7.5, 50% oxygen, without gas‐sparging (which damaged cells) and with mechanical agitation (which directly increased enucleation). O2 consumption was low (~5 × 10–8 μg/cell.h) theoretically enabling erythroblast densities in excess of 5 × 108/ml in commercial bioreactors and sub‐10 l/unit production volumes. The bioreactor process achieved a 24% and 42% reduction in media volume and culture time, respectively, relative to unoptimized flask processing. However, media exchange limited productivity to 1 unit of erythroblasts per 500 l of media. Systematic replacement of media constituents, as well as screening for inhibitory levels of ammonia, lactate and key cytokines did not identify a reason for this limitation. We conclude that the properties of erythroblasts are such that the conventional constraints on cell manufacturing efficiency, such as mass transfer and metabolic demand, should not prevent high intensity production; furthermore, this could be achieved in industry standard equipment. However, identification and removal of an inhibitory mediator is required to enable these economies to be realized. Copyright © 2016 The Authors Journal of Tissue Engineering and Regenerative Medicine Published by John Wiley & Sons Ltd.
- Published
- 2017
15. On your marks, get SET(D1A): the race to protect stalled replication forks
- Author
-
Begum, Shabana, Goula, Amalia, Bayley, Rachel, and Higgs, Martin R.
- Subjects
replication stress ,Genome stability ,FANCD2 ,SETD1A ,Author’s Views ,Chemoresistance ,CHD4 - Abstract
We recently identified that methylation of lysine 4 of histone H3 (H3K4) by SETD1A (SET domain containing 1A) maintains genome stability by protecting newly-replicated DNA from degradation. Mechanistically, SETD1A-dependent histone methylation regulates nucleosome mobilisation by FANCD2 (FA complementation group D2), a crucial step in maintaining genome integrity with important implications in chemo-sensitivity.
- Published
- 2018
16. MYBL2 mRNA expression as a potential biomarker of therapeutic response to genotoxic treatments in myelodysplastic syndrome
- Author
-
Bayley, Rachel, primary, Blakemore, Daniel, additional, and García, Paloma, additional
- Published
- 2018
- Full Text
- View/download PDF
17. MYBL2 Supports DNA Double Strand Break Repair in Hematopoietic Stem Cells
- Author
-
Bayley, Rachel, primary, Blakemore, Daniel, additional, Cancian, Laila, additional, Dumon, Stephanie, additional, Volpe, Giacomo, additional, Ward, Carl, additional, Almaghrabi, Ruba, additional, Gujar, Jidnyasa, additional, Reeve, Natasha, additional, Raghavan, Manoj, additional, Higgs, Martin R., additional, Stewart, Grant S., additional, Petermann, Eva, additional, and García, Paloma, additional
- Published
- 2018
- Full Text
- View/download PDF
18. Basic science232. Certolizumab pegol prevents pro-inflammatory alterations in endothelial cell function
- Author
-
Heathfield, Sarah, Parker, Ben, Zeef, Leo, Bruce, Ian, Alexander, Yvonne, Collins, Fraser, Stone, Michael, Wang, Edward, Williams, Anwen S., Wright, Helen L., Thomas, Huw B., Moots, Robert J., Edwards, Steven W., Bullock, Craig, Chapman, Victoria, Walsh, David A., Mobasheri, Ali, Kendall, David, Kelly, Sara, Bayley, Rachel, Buckley, Chris D., Young, Stephen P., Rump-Goodrich, Lisa, Middleton, Jim, Chen, Liye, Fisher, Roman, Kollnberger, Simon, Shastri, Nilabh, Kessler, Benedikt M., Bowness, Paul, Nazeer Moideen, Abdul, Evans, Laura, Osgood, Louise, Jones, Simon A., Nowell, Mari A., Mahadik, Younis, Young, Stephen, Morgan, Matthew, Gordon, Caroline, Harper, Lorraine, Giles, Joanna L., Paul Morgan, B., Harris, Claire L., Rysnik, Oliwia J., McHugh, Kirsty, Payeli, Sravan, Marroquin, Osiris, Shaw, Jacqueline, Renner, Christoph, Nayar, Saba, Cloake, Tom, Bombardieri, Michele, Pitzalis, Costantino, Buckley, Chris, Barone, Francesca, Lane, Peter, Coles, Mark, Williams, Emma L., Edwards, Christopher J., Cooper, Cyrus, Oreffo, Richard O., Dunn, Sara, Crawford, Aileen, Wilkinson, Mark, Le Maitre, Christine, Bunning, Rowena, Daniels, Jodie, Phillips, Kate L. E., Chiverton, Neil, Le Maitre, Christine L., Shaw, Jackie, Ridley, Anna, Wong-Baeza, Isabel, Keidel, Sarah, Chan, Antoni, Gullick, Nicola J., Abozaid, Hanan S., Jayaraj, David M., Evans, Hayley G., Scott, David L., Choy, Ernest H., Taams, Leonie S., Hickling, M., Golor, G., Jullion, A., Shaw, S., Kretsos, K., Bari, Syed F., Rhys-Dillon, Brian, Amos, Nicholson, Siebert, Stefan, Bunning, Rowena D., Haddock, Gail, Cross, Alison K., Kate, I., Phillips, E., Cross, Alison, Bunning, Rowena A. D., Ceeraz, Sabrina, Spencer, Jo, Choy, Ernest, Corrigall, Valerie, Crilly, Anne, Palmer, Helen, Lockhart, John, Plevin, Robin, Ferrell, William R., McInnes, Iain, Hutchinson, David, Perry, Liz, DiCicco, Maria, Humby, Frances, Kelly, Stephen, Hands, Rebecca, McInnes, Ian, Taylor, Peter, Mehta, Puja, Mitchell, Adam, Tysoe, Carolyn, Caswell, Richard, Owens, Martina, Vincent, Tonia, Hashmi, Tahir M., Price-Forbes, Alec, Sharp, Charlotte A., Murphy, Helen, Wood, Elizabeth F., Doherty, Teresa, Sheldon, Jo, Sofat, Nidhi, Goff, Iain, Platt, Philip N., Abdulkader, Rita, Clunie, Gavin, Ismajli, Mediola, Nikiphorou, Elena, Young, Adam, Tugnet, Nicola, Dixey, Josh, Banik, Snehashish, Alcorn, Desmond, Hunter, John, Win Maw, Win, Patil, Pravin, Hayes, Fiona, Main Wong, Way, Borg, Frances A., Dasgupta, Bhaskar, Malaviya, Anshuman P., Ostor, Andrew J., Chana, Jasroop K., Ahmed, Azeem A., Edmonds, Sally, Coward, Lucy, Borg, Frances, Heaney, Jonathan, Amft, Nicole, Simpson, John, Dhillon, Veena, Ayalew, Yezenash, Khattak, Fazlihakim, Gayed, Mary, Amarasena, Roshan I., McKenna, Frank, Mc Laughlin, Maeve, Baburaj, Krishnan, Fattah, Zozik, Ng, Nora, Wilson, Jo, Colaco, Bernard, Williams, Mark R., Adizie, Tochukwu, Casey, Matthew, Lip, Stefanie, Tan, Shaun, Anderson, David, Robertson, Calum, Devanny, Ian, Field, Max, Walker, David, Robinson, Sandra, Ryan, Sarah, Hassell, Andrew, Bateman, James, Allen, Maggie, Davies, David, Crouch, Carina, Walker-Bone, Karen, Gainsborough, Nicola, Lutalo, Pamela M., Davies, Ursula M., Mckew, Jennifer R., Millar, Auleen M., Wright, Stephen A., Bell, Aubrey L., Thapper, Muryum, Roussou, Thalia, Cumming, Jo, Hull, Richard G., McKeogh, John, O'Connor, Mortimer B., Hassan, Ahmed I., Bond, Ursula, Swan, Joan, Phelan, Mark J., Coady, David, Kumar, Namita, Farrow, Luke, Bukhari, Marwan, Oldroyd, Alexander G., Greenbank, Cathi, McBeth, John, Duncan, Rosie, Brown, Deborah, Horan, Michael, Pendleton, Neil, Littlewood, Alison, Cordingley, Lis, Mulvey, Matthew, Curtis, Elizabeth M., Cole, Zoe A., Crozier, Sarah R., Georgia, Ntani, Robinson, Siân M., Godfrey, Keith M., Sayer, Avan A., Inskip, Hazel M., Harvey, Nicholas C., Davies, Rebecca, Mercer, Louise, Galloway, James, Low, Audrey, Watson, Kath, Lunt, Mark, Symmons, Deborah, Hyrich, Kimme, Chitale, Sarang, Estrach, Cristina, Goodson, Nicola J., Rankin, Elizabeth, Jiang, C. Q., Cheng, K. K., Lam, T. H., Adab, Peymané, Ling, Stephanie, Humphreys, Jennifer, Ellis, Corrinne, Bunn, Diane, Verstappen, Suzanne M., Fluess, Elisa, Macfarlane, Gary J., Bond, Christine, Jones, Gareth T., Scott, Ian C., Steer, Sophia, Lewis, Cathryn M., Cope, Andrew, Mulvey, Matthew R., Lovell, Karina, Keeley, Philip, Woby, Steve, Beasley, Marcus, Viatte, Sebastien, Plant, Darren, Fu, Bo, Solymossy, Csilla, Worthington, Jane, Barton, Anne, Williams, Frances M., Osei-Bordom, Daniel-Clement, Popham, Maria, MacGregor, Alex, Spector, Tim, Little, Jayne, Herrick, Ariane, Pushpakom, S., Ennis, H., McBurney, H., Worthington, J., Newman, W., Ibrahim, Ibrahim, Morgan, Anne, Wilson, Anthony, Isaacs, John, Sanderson, Tessa, Hewlett, Sarah, Calnan, Michael, Morris, Marianne, Raza, Karim, Kumar, Kanta, Cardy, Caroline M., Pauling, John D., Jenkins, Jessica, Brown, Sue J., McHugh, Neil, Mugford, Miranda, Davies, Charlotte, Cooper, Nicola, Brooksby, Alan, Dures, Emma, Ambler, Nick, Fletcher, Debbie, Pope, Denise, Robinson, Frances, Rooke, Royston, Gorman, Claire L., Reynolds, Piero, Hakim, Alan J., Bosworth, Ailsa, Weaver, Dan, Kiely, Patrick D., Skeoch, Sarah, Jani, Meghna, Amarasena, Roshan, Rao, Chandini, Macphie, Elizabeth, McLoughlin, Yokemei, Shah, Preeti, Else, Sara, Semenova, Olga, Thompson, Helen, Ogunbambi, Olabambo, Kallankara, Sathish, Patel, Yusuf, Baguley, Elaine, Halsey, John, Severn, Andrew, Selvan, Shilpa, Price, Elizabeth, Husain, Muhammad J., Brophy, Sinead, Phillips, Ceri J., Cooksey, Roxanne, Irvine, Elizabeth, Lendrem, Dennis, Mitchell, Sheryl, Bowman, Simon, Pease, Colin T., Emery, Paul, Andrews, Jacqueline, Sutcliffe, Nurhan, Lanyon, Peter, Gupta, Monica, McLaren, John, Regan, Marian, Cooper, Annie, Giles, Ian, Isenberg, David, Griffiths, Bridget, Foggo, Heather, Edgar, Suzanne, Vadivelu, Saravanan, Ng, Wan-Fai, Iqbal, Itrat, Heron, Louise, Pilling, Claire, Marks, Jonathan, Hull, Richard, Ledingham, Jo, Han, Chenglong, Gathany, Tim, Tandon, Neeta, Hsia, Elizabeth, Taylor, P., Strand, V., Sensky, T., Harta, N., Fleming, S., Kay, Lesley, Rutherford, Michelle, Nicholl, Karl, Eyre, Tracey, Wilson, Gillian, Johnson, Phil, Russell, M., Timoshanko, J., Duncan, G., Spandley, A., Roskell, S., West, Louise, Adshead, Rebecca, Donnelly, Simon P., Ashton, Simon, Tahir, Hasan, Patel, Dipti, Darroch, James, Boulton, John, Ellis, Benjamin, Finlay, Ron, Murray-Brown, William, Priori, R., Tappuni, T., Vartoukian, S., Seoudi, N., Picarelli, G., Fortune, F., Valesini, G., Pitzalis, C., Bombardieri, M., Ball, Elisabeth, Rooney, Madeleine, Bell, Aubrey, Mérida, Angeles Acosta, Tarelli, Edward, Axford, John, Pericleous, Charis, Pierangeli, Silvia S., Ioannou, John, Rahman, Anisur, Alavi, Azita, Hughes, Michael, Evans, Bronwen, Zaki, Awal, Hui, Michelle, Garner, Rozeena, Rees, Frances, Bavakunji, Riaz, Daniel, Priya, Varughese, Sneha, Srikanth, Asha, Andres, Mariano, Pearce, Fiona, Leung, Jansen, Lim, Ken, Oomatia, Amin, Petri, Michelle, Fang, Hong, Birnbaum, Julius, Amissah-Arthur, Maame, Stewart, Kirsty, Jennens, Hannah, Braude, Simon, Sutton, Emily J., Watson, Kath D., Yee, Chee-Seng, Jayne, David, Akil, Mohammed, Ahmad, Yasmeen, D'Cruz, David, Khamashta, Munther, Teh, Lee-Suan, Zoma, Asad, Dey, Ida D., Kenu, Ernest, Garza-Garcia, Acely, Murfitt, Lucy, Driscoll, Paul C., Pierangeli, Silvia, Ioannou, Yiannis, Reynolds, John A., Ray, David W., O'Neill, Terence, Segeda, Iuliia, Shevchuk, Sergii, Kuvikova, Inna, Brown, Nina, Venning, Michael, Dhanjal, Mandish, Mason, Justin, Nelson-Piercy, Catherine, Basu, Neil, Paudyal, Priya, Stockton, Marie, Lawton, Sally, Dent, Caroline, Kindness, Kathy, Meldrum, Gillian, John, Elizabeth, Arthur, Catherine, West, Lucy, Macfarlane, Matthew V., Reid, David M., Yates, Max, Loke, Yoon, Watts, Richard, Christidis, Dimitrios, Williams, Mark, Sivakumar, Rajappa, Misra, Ramnath, Danda, Debashish, Mahendranath, K. M., Bacon, Paul A., and Mackie, Sarah L.
- Abstract
Background: Cardiovascular disease is a major comorbidity of rheumatoid arthritis (RA) and a leading cause of death. Chronic systemic inflammation involving tumour necrosis factor alpha (TNF) could contribute to endothelial activation and atherogenesis. A number of anti-TNF therapies are in current use for the treatment of RA, including certolizumab pegol (CZP), (Cimzia ®; UCB, Belgium). Anti-TNF therapy has been associated with reduced clinical cardiovascular disease risk and ameliorated vascular function in RA patients. However, the specific effects of TNF inhibitors on endothelial cell function are largely unknown. Our aim was to investigate the mechanisms underpinning CZP effects on TNF-activated human endothelial cells. Methods: Human aortic endothelial cells (HAoECs) were cultured in vitro and exposed to a) TNF alone, b) TNF plus CZP, or c) neither agent. Microarray analysis was used to examine the transcriptional profile of cells treated for 6 hrs and quantitative polymerase chain reaction (qPCR) analysed gene expression at 1, 3, 6 and 24 hrs. NF-κB localization and IκB degradation were investigated using immunocytochemistry, high content analysis and western blotting. Flow cytometry was conducted to detect microparticle release from HAoECs. Results: Transcriptional profiling revealed that while TNF alone had strong effects on endothelial gene expression, TNF and CZP in combination produced a global gene expression pattern similar to untreated control. The two most highly up-regulated genes in response to TNF treatment were adhesion molecules E-selectin and VCAM-1 (q < 0.00005). This was supported by qPCR analysis at 6 hrs (E-selectin and VCAM-1; 208.5 fold and 40.5, respectively above control) and also at 1, 3 and 24 hrs (E-selectin; 25.6, 93.5, 12.7 fold, respectively) (VCAM-1; 4.7, 47.2, 17.6 fold) (n = 3; p < 0.05). In contrast, HAoECs treated with TNF in combination with CZP exhibited control levels of E-selectin and VCAM-1 transcript (p > 0.2 compared to control; p > 0.05 compared to TNF alone). The NF-κB pathway was confirmed as a downstream target of TNF-induced HAoEC activation, via nuclear translocation of NF-κB and degradation of IκB, effects which were abolished by treatment with CZP. In addition, flow cytometry detected an increased production of endothelial microparticles in TNF-activated HAoECs, which was prevented by treatment with CZP. Conclusions: We have found at a cellular level that a clinically available TNF inhibitor, CZP reduces the expression of adhesion molecule expression, and prevents TNF-induced activation of the NF-κB pathway. Furthermore, CZP prevents the production of microparticles by activated endothelial cells. This could be central to the prevention of inflammatory environments underlying these conditions and measurement of microparticles has potential as a novel prognostic marker for future cardiovascular events in this patient group. Disclosure statement: Y.A. received a research grant from UCB. I.B. received a research grant from UCB. S.H. received a research grant from UCB. All other authors have declared no conflicts of interest
- Published
- 2017
19. Oral Abstracts 7: RA Clinical * O37. Long-Term Outcomes of Early RA Patients Initiated with Adalimumab Plus Methotrexate Compared with Methotrexate Alone Following a Targeted Treatment Approach
- Author
-
Fleischmann, Roy, van Vollenhoven, Ronald F., Smolen, Josef, Emery, Paul, Florentinus, Stefan, Rathmann, Suchitrita, Kupper, Hartmut, Kavanaugh, Arthur, Taylor, Peter, Genovese, Mark, Keystone, Edward C., Drescher, Edit, Berclaz, Pierre-Yves, Lee, Chin, Fidelus-Gort, Rosalind, Schlichting, Douglas, Beattie, Scott, Luchi, Monica, Macias, William, Dikranian, Ara H., Alten, Rieke, Klearman, Micki, Musselman, David, Agarwal, Sunil, Green, Jennifer, Gabay, Cem, Weinblatt, Michael E., Schiff, Michael H., Valente, Robert, van der Heijde, Desiree, Citera, Gustavo, Zhao, Cathy, Maldonado, Michael A., Rakieh, Chadi, Nam, Jacqueline L., Hunt, Laura, Villeneuve, Edith, Bissell, Lesley-Anne, Das, Sudipto, Conaghan, Philip, McGonagle, Dennis, Wakefield, Richard J., Wright, Helen L., Thomas, Huw B., Moots, Robert, Edwards, Steven W., Hamann, Philip, Heward, James, McHugh, Neil, Lindsay, Mark A., Haroon, Muhammad, Giles, Jon T., Winchester, Robert, FitzGerald, Oliver, Karaderi, Tugce, Cohen, Carla J., Keidel, Sarah, Appleton, Louise H., Macfarlane, Gary J., Siebert, Stefan, Evans, David, Paul Wordsworth, B., Plant, Darren, Bowes, John, Orozco, Gisela, Morgan, Ann W., Wilson, Anthony G., Isaacs, John, Barton, Anne, Williams, Frances M., Livshits, Gregory, Spector, Tim, MacGregor, Alexander, Scollen, Serena, Cao, Dandan, Memari, Yasin, Hyde, Craig L., Zhang, Baohong, Sidders, Benjamin, Ziemek, Daniel, Shi, Yujian, Harris, Juliette, Harrow, Ian, Dougherty, Brian, Malarstig, Anders, McEwen, Robert, Stephens, Joel L., Patel, Ketan, Shin, So-Youn, Surdulescu, Gabriela, He, Wen, Jin, Xin, McMahon, Stephen B., Soranzo, Nicole, John, Sally, Wang, Jun, Spector, Tim D., Baker, Jonathan, Litherland, Gary J., Rowan, Andrew D., Kite, Kerry A., Bayley, Rachel, Yang, Peiming, Smith, Jacqueline P., Williams, Julie, Harper, Lorraine, Kitas, George D., Buckley, Christopher, Young, Stephen P., Fitzpatrick, Martin A., McGettrick, Helen M., Filer, Andrew, Raza, Karim, Nash, Gerard, Muthana, Munitta, Davies, Holly, Khetan, Sachin, Adeleke, Gbadebo, Hawtree, Sarah, Tazzyman, Simon, Morrow, Fiona, Ciani, Barbara, Wilson, Gerry, Quirke, Anne-Marie, Lugli, Elena, Wegner, Natalia, Charles, Peter, Hamilton, Bart, Chowdhury, Muslima, Ytterberg, Jimmy, Potempa, Jan, Fisher, Benjamin, Thiele, Geoffrey, Mikuls, Ted, Venables, Patrick, Adebajo, Adewale O., Mease, Philip, Gomez-Reino, Juan J., Wollenhaupt, Jurgen, Hu, ChiaChi, Stevens, Randall, Sieper, Joachim, Dougados, Maxime, Van den Bosch, Filip, Goupille, Philippe, Rathmann, Suchitrita S., Pangan, Aileen L., Maksymowych, Walter P., Brown, Matthew A., Elewaut, Dirk, Anderson, Jaclyn, Ramasamy, Pathma, O'Rourke, Michael, Murphy, Conor, Fitzgerald, Oliver, Jani, Meghna, Moore, Sarah, Mirjafari, Hoda, Macphie, Elizabeth, Chinoy, Hector, Rao, Chan, McLoughlin, Yokemei, and Preeti, Shah
- Subjects
medicine.medical_specialty ,Rheumatology ,business.industry ,Radiography ,medicine ,Pharmacology (medical) ,Inflammation ,In patient ,Radiology ,medicine.symptom ,Axial spondyloarthritis ,business ,Joint (geology) - Abstract
Background: This analysis assessed, on a group level, whether there is a long-term advantage for early RA patients treated with adalimumab (ADA) + MTX vs those initially treated with placebo (PBO) + MTX who either responded to therapy or added ADA following inadequate response (IR). Methods: OPTIMA was a 78- week, randomized, controlled trial of ADA + MTX vs PBO + MTX in MTX-naïve early (
- Published
- 2013
20. The productivity limit of manufacturing blood cell therapy in scalable stirred bioreactors.
- Author
-
Bayley, Rachel, Ahmed, Forhad, Glen, Katie, McCall, Mark, Stacey, Adrian, and Thomas, Robert
- Published
- 2018
- Full Text
- View/download PDF
21. DNA Repair Mechanisms in Stem Cells and Implications during Ageing
- Author
-
Bayley, Rachel, primary
- Full Text
- View/download PDF
22. The autoimmune-associated genetic variant PTPN22 R620W enhances neutrophil activation and function in patients with rheumatoid arthritis and healthy individuals
- Author
-
Bayley, Rachel, primary, Kite, Kerry A, additional, McGettrick, Helen M, additional, Smith, Jacqueline P, additional, Kitas, George D, additional, Buckley, Christopher D, additional, and Young, Stephen P, additional
- Published
- 2014
- Full Text
- View/download PDF
23. Does Oxidative Inactivation of CD45 Phosphatase in Rheumatoid Arthritis Underlie Immune Hyporesponsiveness?
- Author
-
Rider, David A., primary, Bayley, Rachel, additional, Clay, Elizabeth, additional, and Young, Stephen P., additional
- Published
- 2013
- Full Text
- View/download PDF
24. Early rheumatoid arthritis and resolving fibroblasts segregate according to Dickkopf related protein 1 expression
- Author
-
Juarez, Maria, primary, Toellner, Dagmar Scheel, additional, Karouzakis, Emmanuel, additional, Hardy, Rowan, additional, Yeo, Lorraine, additional, Bayley, Rachel, additional, de Paz, Banesa, additional, Raza, Karim, additional, Cooper, Mark, additional, Gay, Steffen, additional, Buckley, Christopher, additional, and Filer, Andrew, additional
- Published
- 2013
- Full Text
- View/download PDF
25. Measuring the specific activity of the protein tyrosine phosphatase Lyp
- Author
-
Bayley, Rachel, primary, Yang, Peiming, additional, Buckley, Christopher D., additional, and Young, Stephen P., additional
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.